{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:17:02Z","timestamp":1790180222865,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Imaging"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jcmg.2019.04.025","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T16:17:53Z","timestamp":1565799473000},"page":"2305-2318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"P2","title":["Why Clinicians Should Care About the\u00a0Cardiac Interstitium"],"prefix":"10.1016","volume":"12","author":[{"given":"Erik B.","family":"Schelbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmg.2019.04.025_bib1","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-018-23062-6","article-title":"Structure and distribution of an unrecognized interstitium in human tissues","volume":"8","author":"Benias","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcmg.2019.04.025_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.yjmcc.2009.08.024","article-title":"The extracellular matrix: at the center of it all","volume":"48","author":"Bowers","year":"2010","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/1050-1738(96)00005-9","article-title":"The cell biology of the cardiac interstitium","volume":"6","author":"Borg","year":"1996","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41569-018-0077-x","article-title":"The interstitium in cardiac repair: role of the immune-stromal cell interplay","volume":"15","author":"Forte","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0735-1097(89)90360-4","article-title":"Cardiac interstitium in health and disease: the fibrillar collagen network","volume":"13","author":"Weber","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.hfc.2011.08.012","article-title":"Changes in the myocardial interstitium and contribution to the progression of heart failure","volume":"8","author":"Eckhouse","year":"2012","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jcmg.2019.04.025_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005619","article-title":"Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics","volume":"10","author":"Schelbert","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2019.04.025_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.jacc.2014.01.068","article-title":"Therapeutic targets in heart failure: refocusing on the myocardial interstitium","volume":"63","author":"Schelbert","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002727","article-title":"Developing new treatments for heart failure: focus on the heart","volume":"9","author":"Gheorghiade","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2019.04.025_bib12","first-page":"97","article-title":"Developing therapies for heart failure with preserved ejection fraction: current state and future directions","volume":"2","author":"Butler","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jcmg.2019.04.025_bib13","series-title":"Molecular Cell Biology","author":"Lodish","year":"2000"},{"key":"10.1016\/j.jcmg.2019.04.025_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.recesp.2016.12.018","article-title":"Role of myocardial collagen in severe aortic stenosis with preserved ejection fraction and symptoms of heart failure","volume":"70","author":"Echegaray","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jcmg.2019.04.025_bib16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.CIR.89.1.151","article-title":"Structural basis of end-stage failure in ischemic cardiomyopathy in humans","volume":"89","author":"Beltrami","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1172\/JCI25397","article-title":"Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction","volume":"116","author":"Perrino","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmg.2019.04.025_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9118","article-title":"The long noncoding RNA Wisper controls cardiac fibrosis and remodeling","volume":"9","author":"Micheletti","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jcmg.2019.04.025_bib21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure, biological and translational perspectives","volume":"71","author":"Gonz\u00e1lez","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib22","first-page":"230","article-title":"CCR2(+) Monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload","volume":"3","author":"Patel","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jcmg.2019.04.025_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI115414","article-title":"Alteration of collagen phenotypes in ischemic cardiomyopathy","volume":"88","author":"Mukherjee","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmg.2019.04.025_bib24","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.118.034609","article-title":"Inhibiting fibronectin attenuates fibrosis and improves cardiac function in a model of heart failure","volume":"138","author":"Valiente-Alandi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jacc.2010.10.024","article-title":"Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction","volume":"57","author":"Kasner","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","article-title":"Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase","volume":"60","author":"Lopez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jcmg.2019.04.025_bib27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajh\/3.10.735","article-title":"Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis","volume":"3","author":"McLenachan","year":"1990","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jcmg.2019.04.025_bib28","first-page":"416","article-title":"Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure","volume":"60","author":"Dai","year":"2012","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2015.10.063","article-title":"Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure","volume":"67","author":"Lopez","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/HJH.0000000000001258","article-title":"Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome","volume":"35","author":"Ravassa","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jcmg.2019.04.025_bib31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/0735-1097(93)90094-H","article-title":"Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint","volume":"21","author":"Yamada","year":"1993","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib32","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/archinte.166.17.1805","article-title":"Amyloidosis and the heart: a comprehensive review","volume":"166","author":"Shah","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jcmg.2019.04.025_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0002-9149(79)90389-8","article-title":"Ischemic heart disease secondary to amyloidosis of intramyocardial arteries","volume":"44","author":"Smith","year":"1979","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib35","first-page":"358","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jcmg.2019.04.025_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2559.1994.tb00513.x","article-title":"Lymphatic amyloidosis, a previously unrecognized form of amyloid deposition in generalized amyloidosis","volume":"24","author":"Kaiserling","year":"1994","journal-title":"Histopathology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib37","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","article-title":"Myocardial edema and prognosis in amyloidosis","volume":"71","author":"Kotecha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","article-title":"Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis","volume":"18","author":"Boldrini","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib40","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"Rocken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2019.04.025_bib42","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcmg.2017.01.025","article-title":"CMR-derived extracellular volume fraction as a marker for myocardial fibrosis: the importance of coexisting myocardial inflammation","volume":"11","author":"Lurz","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib44","article-title":"Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1","author":"Treibel","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1532-429X-15-92","article-title":"Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement","volume":"15","author":"Moon","year":"2013","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2019.04.025_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2019.04.025_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1148\/radiol.2018180226","article-title":"Native T1 and extracellular volume measurements by cardiac MRI in healthy adults: a meta-analysis","volume":"290","author":"Gottbrecht","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib48","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2016.02.054","article-title":"Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete's heart","volume":"67","author":"Swoboda","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacc.2017.12.035","article-title":"Reverse myocardial remodeling following valve replacement in patients with aortic stenosis","volume":"71","author":"Treibel","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib50","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","article-title":"Cardiac magnetic resonance T1 mapping in cardiac amyloidosis","volume":"11","author":"Duca","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib51","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1148\/radiol.12112458","article-title":"Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT","volume":"264","author":"Nacif","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1148\/radiol.13130130","article-title":"Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings","volume":"269","author":"Bandula","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcct.2012.10.010","article-title":"3D left ventricular extracellular volume fraction by low-radiation dose cardiac CT: assessment of interstitial myocardial fibrosis","volume":"7","author":"Nacif","year":"2013","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jcmg.2019.04.025_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcct.2016.02.001","article-title":"Estimation of myocardial extracellular volume fraction with cardiac CT in subjects without clinical coronary artery disease: a feasibility study","volume":"10","author":"Kurita","year":"2016","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jcmg.2019.04.025_bib55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jcct.2017.02.006","article-title":"Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: synthetic ECV by CCT","volume":"11","author":"Treibel","year":"2017","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jcmg.2019.04.025_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1148\/radiol.2016151289","article-title":"Myocardial extracellular volume fraction with dual-energy equilibrium contrast-enhanced cardiac CT in nonischemic cardiomyopathy: a prospective comparison with cardiac MR imaging","volume":"280","author":"Lee","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib57","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1093\/eurheartj\/ehy421","article-title":"Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction","volume":"39","author":"Santema","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib58","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2019.04.025_bib59","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","article-title":"Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction","volume":"135","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurheartj\/ehy713","article-title":"Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults","volume":"40","author":"Shanbhag","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib61","article-title":"Myocardial damage detected by late gadolinium enhancement cardiovascular magnetic resonance is associated with subsequent hospitalization for heart failure","volume":"2","author":"Wong","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcmg.2019.04.025_bib62","article-title":"Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage","volume":"4","author":"Schelbert","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcmg.2019.04.025_bib63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","article-title":"Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission","volume":"35","author":"Wong","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib64","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/CIRCULATIONAHA.111.089409","article-title":"Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality","volume":"126","author":"Wong","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib65","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jcmg.2018.08.021","article-title":"Comparing CMR mapping methods and myocardial patterns toward heart failure outcomes in nonischemic dilated cardiomyopathy","volume":"12","author":"Vita","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib66","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ehjci\/jey140","article-title":"Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis","volume":"20","author":"Ambale-Venkatesh","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jcmg.2019.04.025_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12968-018-0477-4","article-title":"Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction","volume":"20","author":"Roy","year":"2018","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2019.04.025_bib68","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1007\/s00330-017-4817-9","article-title":"Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study","volume":"27","author":"Youn","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib69","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib70","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib71","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12880-016-0173-5","article-title":"A\u00a0case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid","volume":"17","author":"Fontana","year":"2017","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.jcmg.2019.04.025_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib77","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Non-biopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2019.04.025_bib79","first-page":"113","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jcmg.2019.04.025_bib80","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","article-title":"Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis","volume":"107","author":"Koyama","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib81","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.amjcard.2011.03.092","article-title":"Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis","volume":"108","author":"Liu","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib82","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2019.04.025_bib83","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/01.CIR.82.3.848","article-title":"A\u00a0comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease","volume":"82","author":"van Hoeven","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib84","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/hrt.55.6.575","article-title":"Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy","volume":"55","author":"Tanaka","year":"1986","journal-title":"Br Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00004872-199816070-00018","article-title":"Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans","volume":"16","author":"Rossi","year":"1998","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jcmg.2019.04.025_bib86","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-2828(08)80028-4","article-title":"The cellular basis of dilated cardiomyopathy in humans","volume":"27","author":"Beltrami","year":"1995","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib87","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib88","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","author":"Brilla","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib89","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","article-title":"Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients","volume":"105","author":"Diez","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib90","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.HYP.36.2.220","article-title":"Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease","volume":"36","author":"Schwartzkopff","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jcmg.2019.04.025_bib91","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib92","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib93","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib94","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","article-title":"Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy","volume":"149","author":"Samuel","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcmg.2019.04.025_bib95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","article-title":"Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease","volume":"64","author":"Samuel","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jcmg.2019.04.025_bib96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib97","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.112.000208","article-title":"Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure","volume":"6","author":"Sabbah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2019.04.025_bib98","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jacc.2016.01.030","article-title":"Matricellular protein CCN5 reverses established cardiac fibrosis","volume":"67","author":"Jeong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ahj.2014.12.001","article-title":"Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators","volume":"169","author":"Butler","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib100","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The Perindopril in Elderly People With Chronic Heart\u00a0Failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2019.04.025_bib101","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib102","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2019.04.025_bib103","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2019.04.025_bib104","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib106","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, Angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jcmg.2019.04.025_bib107","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3389\/fphar.2017.00855","article-title":"Drugs and targets in fibrosis","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcmg.2019.04.025_bib108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.110.217737","article-title":"Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation","volume":"106","author":"Leask","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.jcmg.2019.04.025_bib109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2019.04.025_bib110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCRESAHA.117.310624","article-title":"Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction","volume":"121","author":"Piccoli","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jcmg.2019.04.025_bib111","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.2013.1063","article-title":"Strategies and opportunities for drug development in heart failure","volume":"309","author":"Butler","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2019.04.025_bib112","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib113","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2019.04.025_bib114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and treatment of cardiac amyloidosis","volume":"12","author":"Gertz","year":"2015","journal-title":"Nat Rev Cardiol"}],"container-title":["JACC: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X19306163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X19306163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:48:40Z","timestamp":1761846520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936878X19306163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":114,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1936878X19306163"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmg.2019.04.025","relation":{},"ISSN":["1936-878X"],"issn-type":[{"value":"1936-878X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Clinicians Should Care About the\u00a0Cardiac Interstitium","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmg.2019.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}